96results about "Radiosensitized materials" patented technology

Method and kit for topical treatment of a skin infection, in particular of superficial skin infections, caused by Staphylococcus aureus. The method comprises the steps of applying a photosensitizer to at least a part of the skin affected by the infection, and subjecting said part of the skin to first photons with a majority energy between 2.8 eV and 3.5 eV at a first energy level; and second photons with a majority energy between 1.24 eV and 1.65 eV at a second energy level, the ratio between the first and the second energy levels being in the range from about 10:1 to 2:1. By the method efficient treatment of Staphylococcus aureus infections can be achieved without the administration of topical antibiotics.

The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryo-preserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

The invention provides methods and compositions for treatment of a subject with a glioma. The methods comprise administering a composition comprising Coenzyme Q10 to the subject by continuous intravenous infusion; and administering radiation therapy to the subject. The composition comprising Coenzyme Q10 may be administered to the subject by continuous intravenous infusion for at least 24 hours before the radiation therapy is initiated.

The invention belongs to the field of medicines, and particularly relates to a nanosheet capable of activating an STING pathway and improving microwave ablation as well as a preparation method and application of the nanosheet. The nanosheet is prepared from MXenes through organic acid treatment, organic alkali dispersion, STING agonist compounding and phospholipid modification, and has good microwave thermal conversion efficiency and an STING pathway activation function. The combined microwave ablation can enhance the immunogenic death of tumor cells, promote the maturation of dendritic cells, doubly activate immune response and effectively inhibit the growth and metastasis of prostatic cancer, provides a new strategy for the treatment of prostatic cancer, and can be used for preparing drugs for treating prostatic cancer.

The present application relates to a kind of radiotherapy sensitization microneedle and its preparation method and application, belong to biological medicine technical field.The radiotherapy sensitization microneedle of the present application includes hyaluronic acid and nano radiosensitizer;The radiotherapy sensitization microneedle is obtained by drying after hyaluronic acid and nano radiosensitizer solution are mixed;The nano radiosensitizer solution is prepared by the following method: hafnium salt, 1,1'-ferrocene dicarboxylic acid and benzoic acid are mixed in organic solvent and stirred, centrifugal;The supernatant obtained is dialyzed, extracted, and the liquid phase obtained after solid-liquid separation is nano radiosensitizer solution.The radiotherapy sensitization microneedle of the present application is applied to the growth inhibition and radiotherapy sensitization of mouse melanoma cell B16F10 cell, can fully play the role of radiotherapy sensitization while overcoming the limitation of prior art, and preparation route is simple, and have certain conversion prospect.

The present disclosure relates generally to methods of utilizing sonosensitizers in the presence of thiamine or a derivative thereof for the purpose of cross-linking animal tissue, producing singlet oxygen within or at the site of animal tissue, or treating a condition in a subject, wherein the condition is an aneurysm, cancer, and / or a scleral condition.

Disclosed herein are boronated amino acid compositions comprising tyrosine derivatives TC220 and TC221 and improved methods of making TC220 and TC221. Thus, the TC220 and / or TC221 can be expanded to commercial scale and administered to patients as neutron trapping agents, and methods of treating cancer, immune disorders, and other diseases by utilizing a neutron capture therapy pattern are provided.

The invention relates to an application of a DNAJB4 gene and an encoding protein thereof in preparation of a product for enhancing cancer radiotherapy sensitivity. The DNAJB4 gene provided by the invention is closely related to cancer radiotherapy sensitivity, and overexpression of the DNAJB4 gene is positively related to radiotherapy sensitivity of head and neck squamous cell carcinoma, cervical cancer or breast cancer. A product prepared from the target DNAJB4 selectively degrades DNA-PKcs through a CMA way, high specificity is achieved, and toxicity to normal tissue can be reduced; the radiotherapy remission rate of a patient with high DNAJB4 expression is obviously improved (clinical queue data); the combined treatment prolongs the median lifetime of the mouse model; the drug resistance risk can be reduced by combining with existing therapies (radiotherapy and immunotherapy).

The present invention relates to the treatment of viral infections using photosensitizers in dairy cattle. The invention also relates to the prevention of transmission of viral infections from dairy cattle infected by virus to the same or other species. The invention is also directed to methods of controlling infectious agents on milking equipment for dairy cattle. The invention is further directed to milking processes including the treatment of viral infections and / or the prevention of transmission of viral infections from dairy cattle infected by virus to the same or other species and / or the methods for controlling infectious agents on milking equipment for dairy cattle.

A method of treating a cancer in a mammalian subject afflicted with the cancer, includes administering to the subject an immune checkpoint inhibitor, and administering to the subject a pentaaza macrocyclic ring complex corresponding to the formula (I) below, prior to, concomitantly with, or after administration of the immune checkpoint inhibitor, to increase the response of the cancer to the immune checkpoint inhibitor.

The invention discloses a tellurium-based nano material capable of efficiently inducing copper death as well as a preparation method and application of the tellurium-based nano material. The preparation method comprises the following steps: by taking water as a medium, mixing soluble copper salt and a sulfydryl-containing compound, and stirring to react, so as to obtain a Cu-S2 solution; dropwise adding the Cu-S2 solution into the TeO2 nano-carrier solution, and carrying out stirring reaction; and after the reaction is finished, carrying out solid-liquid separation, taking the solid, and resuspending with methanol to obtain the TeO2 coated Cu-S2 nano material. The preparation method is simple and rapid, large-scale production can be achieved, and the obtained TeO2 coated Cu-S2 nano material can efficiently induce cancer cells to generate copper death, is effective to various cancer cells and has potential clinical transformation application prospects.

Provided is a Pt(IV) complex. As a prodrug, the Pt(IV) complex is activated by irradiation to release a Pt(II) complex for the treatment of tumors. Also provided is a pharmaceutical composition including the Pt(IV) complex, and the use of the Pt(IV) complex in the preparation of a drug for treating tumors by means of irradiation activation. Further provided is a kit including the Pt(IV) complex and the description, wherein the description indicates that radiotherapy is performed after administration to treat tumors.

Borylated Amino Acid compositions comprising tyrosine derivatives TC220 and TC221 and improved methods of making TC220 and TC221 are disclosed herein. Consequently, the TC220 and / or TC221 can be scaled up to commercial scale and administered to patients as a Neutron Capture Agent and provide a method of treating cancer, immunological disorders, and other disease by utilizing a Neutron Capture Therapy modality.

Provided are a fluorine-18-labeled positron emission tomography (PET) radiotracer for diagnosing neuroinflammation, stroke or cerebral infarction and a method for diagnosing cancer in a subject including administering a fluorine-18-labeled PET radiotracer a subject, obtaining in vivo PET images of the uptake of the fluorine-18-labeled positron emission tomography (PET) radiotracer in a lesion in the subject, and evaluating the uptake of the fluorine-18-labeled radiotracer in the lesion.

The invention relates to novel biocompatible hybrid nanoparticles of very small size, useful in particular for diagnostics and / or therapy.The purpose of the invention is to offer novel nanoparticles which are useful in particular as contrast agents in imaging (e.g. MRD and / or in other diagnostic techniques and / or as therapeutic agents, which give better performance than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high loading with metals (e.g. rare earths), in particular so as to have, in imaging (e.g. MRI), strong intensification and a correct response (increased relaxivity) at high frequencies.Thus, the nanoparticles according to the invention, with diameter d1 between 1 and 20 nm, each comprise a polyorganosiloxane (POS) matrix including gadolinium cations optionally associated with doping cations; a chelating graft C1 DTPABA (diethylenetriaminepentaacetic acid bisanhydride) bound to the POS matrix by an —Si—C— covalent bond, and present in sufficient quantity to be able to complex all the gadolinium cations; and optionally another functionalizing graft Gf* bound to the POS matrix by an —Si—C— covalent bond (where Gf* can be derived from a hydrophilic compound (PEG); from a compound having an active ingredient PA1; from a targeting compound; from a luminescent compound (fluorescein).The method for the production of these nanoparticles and the applications thereof in imaging and in therapy also form part of the invention.

The present invention relates to a micelle complex and a drug carrier. By supporting hydrophobic manganese oxide particles in the micelles, the complex is stably protected in vivo and easily delivered to a tumor site. Further, the micelles have a hydrophilic portion and a hydrophobic portion bound by a reactive oxygen species (ROS) cleavable linker in order to be degraded in response to a reactive oxygen species of a target site, and thus can efficiently release the hydrophobic manganese oxide particles. The released hydrophobic manganese oxide particles generate oxygen and changes the microenvironment of the target site, and thus may enhance the therapeutic effect of a drug carried on the micelles.

This invention relates to the field of biomedical technology. The invention discloses a method for preparing nanomaterials that can improve the radiosensitivity of tumors and their applications, comprising: S1: dissolving tungsten and copper compounds in an organic solvent in a specific ratio to prepare a mixed solution; S2: transferring the solution to a reaction vessel, adding a surfactant or polymer, and reacting at a certain temperature to form rod-shaped initial nanomaterials; S3: cooling to room temperature, centrifuging and washing to obtain a moist material; S4: drying to obtain Cu-W. 18 O 49 Nanomaterials. The Cu-W of this invention 18 O 49 Nanomaterials can be injected intravenously or intratumorally to target tumors via the EPR effect. When combined with near-infrared light and X-ray therapy, the photothermal effect raises the temperature, improves hypoxia, and enhances the killing effect of radiotherapy. It is suitable for triple-negative breast cancer, etc., inhibiting tumors through the secondary electrons of tungsten, the Fenton reaction of copper ions, and the photothermal effect. It can be monitored by CT or photoacoustic imaging, and can activate the immune response when used in combination with immune checkpoint inhibitors.

The present invention is in the field of pre-functionalized nanoparticles (NPs). It more particularly relates to the use of NPs pre-functionalized with self-assembled monolayers (SAMs), and also to the use of NPs functionalized with biomolecules, such that the NPs are stable in solution. These NPs can be used in a variety of applications, in particular as diagnostic tools, depletion tools of target molecules in solution, and therapeutic tools.

The current invention relates to a combination therapy comprising administering the antimitotic agent ABT-751 to a subject and delivering ionizing radiation to the same subject for the treatment of a brain tumor. Provided is for ABT-751 and ionizing radiation for use in such treatments.

A radiotherapy treatment system and method used for conducting radiographic X-ray imaging on a target organ during radiographic treatment. The system comprises (a) an x-ray beam source configurable to deliver an X-ray beam to a target organ, (b) optical means for converging and shaping said beam to a cone-shaped X-ray beam of photons which hit the target organ simultaneously, (c) multiple high-Z nanoparticles attachable to the target organ, said high-Z nanoparticles absorbing said X-ray radiation and emitting X-ray fluorescence (XRF) photons, (d) at least one XRF detector for detecting said XRF photons ejecting out of a patient's body, and (e) control means for controlling the radiotherapy treatment procedure. The x-ray beam is focusable on a section in the target organ where the concentration of said high-Z nanoparticles leading to a desirable emission of said XRF photons, and in case the emission of said XRF photons decreases, the x-ray beam is movable to refocus on the section in the target organ where the emission of said XRF photons is desirable.

The present invention relates to the field of prefunctionalized nanoparticles (NPs). More particularly, the present invention relates to NPs prefunctionalized with self-assembled monolayers (SAMs) and functionalized with biomolecules such that the NPs are stable in solution. These NPs can be used in many applications, particularly as diagnostic tools, tools for depleting molecules of interest in solution, and therapeutic tools.

Disclosed herein are compositions and methods useful for treating hemoglobinopathies and blood disorders. The compositions comprise an actinium-225-labeled anti-CD45 antibody (BC8) formulated as a single patient dose that can be completely delivered to the patient in a single dose. The actinium-225-labeled anti-CD45 may be administered alone or in combination with additional therapeutic agents, such as other immunotherapeutics or radiosensitizers, or additional therapeutic interventions, such as bone marrow transplantation or adoptive cell therapy.

The invention provides a recombinant Newcastle disease virus for expressing anti-VEGFR2 ScFv-Fc, a recombinant Newcastle disease virus genome, a DNA molecule for coding the recombinant Newcastle disease virus genome, a pharmaceutical composition containing the recombinant Newcastle disease virus genome, and applications of the recombinant Newcastle disease virus and the recombinant Newcastle disease virus. According to the invention, the coding gene of the anti-VEGFR2 ScFv-Fc is inserted between the P gene and the M gene of the Newcastle disease virus genome, so that the radiotherapy effect in the tumor or cancer treatment process can be obviously enhanced.

Disclosed herein are metabolizable binary gold supraclusters, which, in some implementations, comprise cationic gold nanoclusters laden with a therapeutic nucleic acid, such as a small interfering RNA (siRNA), and are intertwined through bioresponsive crosslinkers within a hydrophilic polymer matrix. Also provided herein are uses of the supraclusters, e.g., in treatment of diseases such as cancers.

Systems and methods for radiation therapy for cancerous tumors using biocompatible quantum dots to provide radiation dose enhancement and resistance to metastasis are described. In an aspect, a method for radiation therapy treatment of cancer cells, includes, but is not limited to, preparing a radiosensitizer fluid, the radiosensitizer fluid including a plurality of biocompatible quantum dots; introducing the radiosensitizer fluid to cancer cells; and irradiating the cancer cells with the radiosensitizer fluid to promote generation of reactive oxygen species and inhibit radiation-induced enhancement of cell-migration.

There is provided with a method of treating cancer. A set of administration of a compound represented by General Formula (I) or a pharmaceutically acceptable salt thereof to a patient, at a dose such that 8 mg / kg or less of the compound represented by General Formula (I) is administered, and irradiation to the patient immediately following the administration is repeated. A total dosage of the irradiation to a cancer is 10 Gy or more.

The present disclosure relates to combinations of cyclin-dependent kinase 7 (CDK7) inhibitors and other therapeutic treatments, in particular other anti-cancer agents, and uses of such combination(s) in the treatment of cancers.

The present invention consists in combining low dose intestinal radiation (ILDR) with immunotherapy or other antineoplastic treatments, in the ideal context of intestinal presence or prevalence of Christensenellaceae family members, especially for solid cancers at an advanced stage (refractory to first line chemo or immunotherapy). The invention also pertains to a bacterial composition,e.g. comprising Chistensenella bacteria, for use in the treatment of cancer in a patient, in combination with intestinal low dose radiotherapy (ILDR) and an antineoplastic treatment.

The application belongs to the technical field of biological medical materials and radiation medicine, and particularly relates to a bismuth-chloride cluster-cucurbit[6]uril-based supramolecular framework material and a preparation method and application thereof. 10 ] 4‑ Anion clusters) as a building unit and cucurbit[6]uril (CB[6]) are fused and co-constructed through host-guest interaction to prepare a supramolecular framework material. The structure and physicochemical properties of the compound are determined through single crystal structure testing and various spectroscopic characterizations, and the application of the compound as a radiotherapy sensitizer is studied. The results of in-vitro and in-vivo biological experiments prove that the material can be used for inhibiting the growth of various cancer cells by significantly sensitizing radiotherapy.

New techniques for remote administration of medicine and medical devices using an external guidance and activation system are provided. In some embodiments, medicine(s) and / or medical device(s) is / are energized to a predetermined threshold energy level by externally applied radiation, and then driven into the treatment target. The design of such device(s) (e.g., injectable machine(s)) may include sub-device(s), e.g., medical payload-carrying reservoir(s), injector(s) and abrasive tool(s), which may be activated magnetically and / or by such radiation. In some aspects, such sub-device(s) include actuable housing(s) and / or other sub-tool(s), delivering drugs to specific locations commanded by a control system or a user. In other aspects, a medicine and / or device is provided with multiple dipoles, each oriented differently in three-dimensional space, allowing a guidance control system, remote from the medicine or device, to drive the movement and three-dimensional orientation of the medical agent or particle according to a three-dimensional path.